Company
Kailera Therapeutics
Hengrui's obesity NewCo: a US company holding ex-China rights to a GLP-1/GIP franchise, now in global Phase 3 and Nasdaq-listed.
1. Core Product / Service
Kailera (Waltham, MA) was incorporated on 2024-05-08 as "Hercules CM Newco" and renamed in August 2024 [1]. It does no discovery of its own: its whole pipeline is in-licensed from Jiangsu Hengrui Pharmaceuticals, with rights covering the world outside Greater China [1].
| Candidate | What it is | Stage (ex-China) |
|---|---|---|
| Ribupatide (KAI-9531 / HRS9531) | Once-weekly injectable GLP-1/GIP dual agonist peptide | Global Phase 3 (KaiNETIC-1/-2/-3, started Dec 2025–Jan 2026; topline expected 2028) [1] |
| Oral ribupatide (KAI-9531-T) | Once-daily tablet of the same peptide | Global Phase 3 planned as early as 1H 2027; Hengrui plans a China Phase 3 [1] |
| KAI-7535 (HRS-7535) | Once-daily oral small-molecule GLP-1 agonist | Global Phase 2 started April 2026 (topline 2027); Hengrui China Phase 3 ongoing [1] |
| KAI-4729 (HRS-4729) | Once-weekly GLP-1/GIP/glucagon tri-agonist | Early clinical (Hengrui Phase 1 in China) [1] |
The clinical case rests on Hengrui's Chinese data: in a 48-week China Phase 3, ribupatide 6 mg produced a mean 17.7% weight reduction (treatment-policy estimand) vs 1.4% for placebo [1].
2. Target Users & Pain Points
- Patients / payers: adults with obesity, with a stated focus on higher-BMI (35+) patients who remain obese on current drugs; KaiNETIC-3 includes an open-label semaglutide arm [1].
- Pain solved for the licensor: Hengrui monetises ex-China rights without building a Western development and commercial organisation, while keeping equity upside.
3. Competitive Landscape
| Player | Asset class | Note |
|---|---|---|
| Eli Lilly (tirzepatide) | Approved GLP-1/GIP | The benchmark Kailera explicitly positions against [1] |
| Novo Nordisk (semaglutide) | Approved GLP-1 | Comparator arm in KaiNETIC-3 [1] |
| verdiva-bio | Oral weekly GLP-1 from Sciwind | Another China-sourced obesity NewCo, earlier stage |
4. Unique Observations
- Wet lab and CMC stay in China. The prospectus states Kailera owns no manufacturing facilities; Hengrui supplies drug substance and drug product for clinical trials under a January 2025 supply agreement, and all Phase 1/2 and China Phase 3 data were generated by Hengrui [1]. Kailera's ~145 staff (98 in R&D at end-2025) run global trials, regulatory and BD — the archetype of the asset-light NewCo [1].
- Licensor equity is a large part of the deal. Headline "upfront" figures of ~$110M in press coverage combine a $100M cash upfront and a $10M technology-transfer fee; on top of that Hengrui received preferred stock worth ~$96.4M at issuance, equal to 19.9% fully diluted [1][2].
- Proof that the NewCo route can reach public markets. Kailera was the first of the 2024–2025 China-asset NewCos to IPO, followed by braveheart-bio in August 2026 and the candid-therapeutics trade sale to UCB [2].
5. Financials / Funding
- Series A: $400M (May 2024; Bain Capital Life Sciences, Atlas Venture, RTW and others) [2][3].
- Series B: $600M (Oct 2025; led by Bain Capital Private Equity) [3]. Note: the prospectus says $900M of proceeds were raised since inception, vs $1.0B implied by the two announced rounds [1][3].
- IPO: Nasdaq KLRA, priced at $16/share on 2026-04-16/17; 39.06M base shares (~$625M) plus a 5.86M-share option, ~$718.8M gross with the option exercised [1][4].
- Hengrui terms: $100M upfront + $10M tech transfer + 19.9% equity; up to $200M clinical/regulatory and up to $5.725B commercial milestones; tiered royalties mid-single-digit to low-tens percent [1].
- Cash: $652.7M at 2025-12-31, pre-IPO [1].
6. People & Relationships
- CEO: Ron Renaud (ex-CEO Cerevel, Translate Bio, Idenix); CMO: Scott Wasserman [1].
- Licensor / supplier / shareholder: Jiangsu Hengrui Pharmaceuticals.
- Investors: Bain Capital (Life Sciences and Private Equity), Atlas Venture, RTW, CPP Investments, Qatar Investment Authority [1][3].
- Peer NewCos: braveheart-bio (also Hengrui), verdiva-bio, candid-therapeutics, timberlyne-therapeutics, windward-bio, sentivera.
Sources
- [1] Kailera Therapeutics, final prospectus (424B4), SEC EDGAR, filed 2026-04-17 (accessed 2026-10-14)
- [2] Research notes on China-asset NewCos, 2026-10-14
- [3] BioPharma Dive, "Kailera Series B, Bain, obesity drugs, Hengrui GLP-1/GIP" (accessed 2026-10-14)
- [4] Kailera press release on IPO closing and full option exercise, via Barchart (accessed 2026-10-14)
Related
Last compiled: 2026-10-14